AxoGen announces publication of 100th peer-reviewed clinical paper.
Axogen announced publication of the 100th peer-reviewed paper featuring results from clinical studies involving its product portfolio. The latest paper, Inferior Alveolar Nerve: To Graft or Not to Graft in Ablative Mandibular Resection? by Maryam Akbari, DMD, MPH, MD, and Michael Miloro, DMD, MD was published in the Journal of Oral and Maxillofacial Surgery. The study explored factors that influence nerve repair in mandible reconstruction and offered techniques and treatment recommendations on how to incorporate nerve repair into the reconstruction. It joins a robust list of publications which represent a depth of clinical evidence from both sponsored and independent investigator studies that cover a range of nerve repair applications including extremity trauma, oral and maxillofacial reconstruction, breast reconstruction neurotization, and repair following the removal of painful neuromas. Research findings were shared over the past ten years in over 40 different peer-reviewed scientific journals and academic publications including The Journal of Hand Surgery, Journal of Oral Maxillofacial Surgery, Microsurgery, Regenerative Medicine, and Annals of Plastic Surgery. Studies of Avance Nerve Graft show positive outcomes while eliminating the donor site comorbidities associated with autograft. The library of 100 publications, spanning the use of Avance Nerve Graft and the Axoguard family of products, includes: Research from nearly 300 surgeon and clinical investigators; More than 90 independent non-sponsored papers, which highlights growing surgeon interest and acceptance of the Axogen portfolio of products; Repair of digital nerves in 37 publications and repair of mixed and motor nerves in 29 publications, with consistent results in short and long gap nerve injuries and sensory, mixed and motor nerve repairs; 18 publications in oral and maxillofacial reconstruction, a growing surgical application; and Six publications featuring data reports from the RANGER Study, with an 85% overall meaningful recovery rate across all nerve repairs in the study.
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 26, 2019|
|Previous Article:||Vocera price target lowered to $36 from $40 at Cantor Fitzgerald.|
|Next Article:||Covia to sell Winchester and Western Railroad for $105M in cash.|